STOCK TITAN
  1. Home
  2. IMGN

Immunogen (IMGN) Stock Price, News & Analysis

IMGN NASDAQ

Company Description

Immunogen (NASDAQ: IMGN) is classified in the pharmaceutical preparation manufacturing industry within the Manufacturing sector.

This page collects what Stock Titan holds for IMGN, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart
$—
-
-
Last updated:
-
Performance 1 year
-
Market Cap
-
Shares outstanding

Latest News

View All
—

Seaport Therapeutics Names Lauren White as Chief Financial Officer

0.00%

AbbVie Completes Acquisition of ImmunoGen

acquisition
-0.34%

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

+0.07%

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

+1.51%

ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

clinical trial
-0.03%

FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer

fda approval

Immunogen has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 3 with negative movement. Key topics include acquisition, clinical trial, fda approval, earnings. View all IMGN news →

SEC Filings

View All

No SEC filings available for IMGN.

Financial Highlights

—
Revenue (latest FY)
—
Net Income (latest FY)
—
Diluted EPS (latest FY)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

IMGN Company Profile & Sector Positioning

Immunogen (IMGN) operates in the Pharmaceutical Preparation Manufacturing industry within the broader Manufacturing sector and is listed on the NASDAQ.